The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Esin R.G.

Kazanskaia gosudarstvennaia meditsinskaia akademiia

Esin O.R.

Kazanskaia gosudarstvennaia meditsinskaia akademiia

Khaĭrullin I.Kh.

GBUZ "Respublikanskaia klinicheskaia bol'nitsa #2" Minzdrava Respubliki Tatarstan, Kazan'

Discirculatory encephalopathy and small vessel disease

Authors:

Esin R.G., Esin O.R., Khaĭrullin I.Kh.

More about the authors

Read: 4689 times


To cite this article:

Esin RG, Esin OR, Khaĭrullin IKh. Discirculatory encephalopathy and small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(8):109‑115. (In Russ.)
https://doi.org/10.17116/jnevro201611681109-113

Recommended articles:
Animal expe­rimental models in the study of age-dependent cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):57-68
Cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):15-24
Radon therapy and high-intensity magnetic therapy in spa treatment of chro­nic dyscirculatory ence­phalopathy. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(3):22-28

References:

  1. Vereshhagin NV, Morgunov VA, Gulevskaja TS. Patologija golovnogo mozga pri ateroskleroze i arterial'noj gipertonii. M.: Medicina; 1997. (In Russ.).
  2. Sosudistye zabolevanija nervnoj sistemy. Pod red. Shmidta EV. M.: Medicina; 1975. (In Russ.).
  3. Levin OS. Discirkuljatornaja jencefalopatija: anahronizm ili klinicheskaja real'nost'. Sovremennaja terapija v psihiatrii i nevrologii. 2012;3:40-46. (In Russ.).
  4. Parfenov VA, Neverovskij DV. Vedenie pacientov s discirkuljatornoj jencefalopatiej v ambulatornoj praktike. Nevrologija, nejropsihiatrija, psihosomatika. 2015;(1):37-42.  doi: 10.14412/2074-2711-2015-1-37-42 (In Russ.).
  5. Kamchatnov PR. Discirkuljatornaja jencefalopatija - nekotorye voprosy kliniki i terapii. Ssylka aktivna na 19.04.16. Dostupno po: http://www.rmj.ru/articles/obshchie-stati/Discirkulyatornaya_encefalopatiya__nekotorye_voprosy_kliniki_i_terapii/ (In Russ.).
  6. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. The Lancet Neurology. 2010;9(7):689-701.  doi: 10.1016/s1474-4422(10)70104-6
  7. Norrving B. Lacunar infarcts: no black holes in the brain are benign. Practical Neurology. 2008;8(4):222-228.  doi: 10.1136/jnnp.2008.153601
  8. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. The Lancet. 2003;362(9391):1211-1224. doi: 10.1016/s0140-6736(03)14544-8
  9. Debette S, Markus H. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341(1):3666-3666. doi: 10.1136/bmj.c3666
  10. Morris Z, Whiteley WN, Longstreth WT, Weber F, Lee Y, Tsushima Y, Alphs H, Ladd SC, Warlow C, Wardlaw JM, Al-Shahi Salman R. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2009;339(1):3016-3016. doi: 10.1136/bmj.b3016
  11. Jackson C, Hutchison A, Dennis M, Wardlaw J, Lewis S, Sudlow C. Differences Between Ischemic Stroke Subtypes in Vascular Outcomes Support a Distinct Lacunar Ischemic Stroke Arteriopathy: A Prospective, Hospital-Based Study. Stroke. 2009;40(12):3679-3684. doi: 10.1161/strokeaha.109.558221
  12. Makin S, Turpin S, Dennis M, Wardlaw J. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. Journal of Neurology, Neurosurgery & Psychiatry. 2013;84 (8):893-900.  doi: 10.1136/jnnp-2012-303645
  13. Windham B, Griswold M, Shibata D, Penman A, Catellier D, Mosley T. Covert Neurological Symptoms Associated With Silent Infarcts From Midlife to Older Age: The Atherosclerosis Risk in Communities Study. Stroke. 2012;43(5):1218-1223. doi: 10.1161/strokeaha.111.643379
  14. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, De Leeuw F, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R. V, Pantoni L, Speck O, Stephan BCM, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, Van Buchem M, Norrving B, Gorelick PB, Dichgans M. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. The Lancet Neurology. 2013;12(8):822-838.  doi: 10.1016/s1474-4422(13)70124-8
  15. Kivipelto M, Helkala E, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001;56(12):1683-1689. doi: 10.1212/wnl.56.12.1683
  16. Dichgans M, Zietemann V. Prevention of Vascular Cognitive Impairment. Stroke. 2012;43(11):3137-3146. doi: 10.1161/strokeaha.112.651778
  17. Schneider J, Arvanitakis Z, Bang W, Bennett D. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204. doi: 10.1212/01.wnl.0000271090.28148.24
  18. Nandigam R, Schneider J, Arvanitakis Z, Bang W, Bennett D. Mixed Brain Pathologies Account For Most Dementia Cases In Community-Dwelling Older Persons. Neurology. 2008;70(10):816-817.  doi: 10.1212/01.wnl.0000307675.38908.39
  19. Gouw AA, Seewann A, Van Der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJG. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. Journal of Neurology, Neurosurgery & Psychiatry. 2010;82(2):126-135.  doi: 10.1136/jnnp.2009.204685
  20. Shoamanesh A, Kwok C, Benavente O. Cerebral Microbleeds: Histopathological Correlation of Neuroimaging. Cerebrovasc Dis. 2011;32(6):528-534.  doi: 10.1159/000331466
  21. De Reuck J, Auger F, Cordonnier C, Deramecourt V, Durieux N, Pasquier F, Bordet R, Maurage C, Leys D. Comparison of 7.0-T T2*-Magnetic Resonance Imaging of Cerebral Bleeds in Post-Mortem Brain Sections of Alzheimer Patients with Their Neuropathological Correlates. Cerebrovasc Dis. 2011;31(5):511-517.  doi: 10.1159/000324391
  22. Bath PM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke. 2015;10(4):469-478.  doi: 10.1111/ijs.12466
  23. Østergaard L, Engeda TS, Moreton F, Hansen MB, Wardlaw JM, Dalkara T, Markus HS, Muir KW. Cerebral small vessel disease: Capillary pathways to stroke and cognitive decline. Journal of Cerebral Blood Flow & Metabolism. 2015:0271678X15606723. doi: 10.1177/0271678x15606723
  24. Grinberg L, Thal D. Vascular pathology in the aged human brain. Acta Neuropathologica. 2010;119(3):277-290.  doi: 10.1007/s00401-010-0652-7
  25. Topol E, Easton D, Harrington R. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. ACC Current Journal Review. 2003;12(6):15.  doi: 10.1016/j.accreview.2003.09.053
  26. Bath PMW, Blann A, Smith N, Butterworth RJ. Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets. 1998;9(3-4):155-159.  doi: 10.1080/09537109876618
  27. Lavallée PC, Labreuche J, Faille D, Huisse M, Nicaise-Roland P, Dehoux M, Gongora-Rivera F, Jaramillo A, Brenner D, Deplanque D, Klein IF, Touboul P, Vicaut E, Ajzenberg N. Circulating Markers of Endothelial Dysfunction and Platelet Activation in Patients with Severe Symptomatic Cerebral Small Vessel Disease.Cerebrovasc Dis. 2013;36(2):131-138.  doi: 10.1159/000353671
  28. Allen C, Bayraktutan U. Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood-brain barrier hyperpermeability. Diabetes, Obesity and Metabolism. 2009;11(5):480-490.  doi: 10.1111/j.1463-1326.2008.00987.x
  29. Allen C, Srivastava K, Bayraktutan U. Small GTPase RhoA and Its Effector Rho Kinase Mediate Oxygen Glucose Deprivation-Evoked In Vitro Cerebral Barrier Dysfunction. Stroke. 2010;41(9):2056-2063. doi: 10.1161/strokeaha.109.574939
  30. Shao B, Bayraktutan U. Hyperglycaemia promotes human brain microvascular endothelial cell apoptosis via induction of protein kinase C-ßI and prooxidant enzyme NADPH oxidase. Redox Biol. 2014;2:694-701.  doi: 10.1016/j.redox.2014.05.005
  31. Farrall AJ, Wardlaw JM. Blood-brain barrier: Ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging. 2009;30:337-352.  doi: http://dx. doi.org/10.1016/j.neurobiolaging.2007.07.015
  32. Bohm M, Cotton D, Foster L, Custodis F, Laufs U, Sacco R, Bath PMW, Yusuf S, Diener H. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. European Heart Journal. 2012;33(22):2804-2812. doi: 10.1093/eurheartj/ehs250
  33. Rothwell PM, Howard SC, Dolan E, O'brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. The Lancet. 2010;375(9718):895-905.  doi: 10.1016/s0140-6736(10)60308-x
  34. Nash K, Shah Z. Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders. Integrative Medicine Insights. 2015:1.  doi: 10.4137/imi.s25054
  35. Jahno NN, Damulin IV, Zaharov VV, Elkin MN, Erohina LG, Stahovskaja LV, Chekneva NS, Suslina ZA, Timerbaeva SL, Fedin PA, Bodareva JeA, Skoromec AA, Sorokoumov VA, Ivashkin VT, Grigor'ev JuV, Pervozvanskij BE. Primenenie tanakana pri nachal'nyh stadijah sosudistoj mozgovoj nedostatochnosti: rezul'taty otkrytogo mnogocentrovogo issledovanija. Nevrologicheskij zhurnal. 1998;6:18-23. (In Russ.).
  36. Timerbaeva SL, Suslina ZA, Bodareva JeA, Fedin PA, Korepina OS, Pervozvanskij B.E. Tanakan v lechenii nachal'nyh projavlenij nedostatochnosti krovosnabzhenija mozga. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2000;8:24-28. (In Russ.).
  37. Jahno NN, Zaharov VV, Lokshina AB, Gavrilova SI, Fedorova JaB, Gustov AV, Korshunova JuA, Dzjak LA, Mizjakina EV, Odinak MM, Emelin AJu, Pilipenko PI, Vostrikova EV. Tanakan (EGb 761) v terapii umerennyh kognitivnyh narushenij (mul'ticentrovoe issledovanie). Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2006;106:12:41-46. (In Russ.).
  38. Parfenov VA, Stachina JuA. Lechenie tanakanom nevrologicheskih rasstrojstv u bol'nyh s arterial'noj gipertenziej. Russkij medicinskij zhurnal. 2005;22:1462-1465. (In Russ.).
  39. Khairullin IKh, Esin RG, Pozdnyak AO. The Potential for Correcting Cognitive Decline in Patients with Type 2 Diabetes Mellitus. Neuroscience and Behavioral Physiology. 2016;46(3):360-364.  doi: 10.1007/s11055-016-0242-9
  40. Naprienko MV, Esin RG, Muhametova JeR, Esin OR, Smekalkina LV. Tanakan - mul'timodal'nyj citoprotektor dlja obshhemedicinskoj praktiki. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;11:146-151.  doi: 10.17116/jnevro2015115111146-151
  41. Esin RG, Naprienko MV, Muhametova JeR, Hajrullin IH, Esin OR. Tanakan - mul'timodal'nyj citoprotektor dlja obshhemedicinskoj praktiki. Obzor (chast' 2). Zhurnal nevrologii i psihiatr. im. S.S. Korsakova. 2015;12:157-162. (In Russ.). doi: 10.17116/jnevro2015115112177-182

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.